Ajanta Net Income vs Begin Period Cash Flow Analysis

AJANTPHARM

2,638 18.00 0.68%

Ajanta Pharma financial indicator trend analysis is way more than just evaluating Ajanta Pharma Limited prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ajanta Pharma Limited is a good investment. Please check the relationship between Ajanta Pharma Net Income and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajanta Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Net Income vs Begin Period Cash Flow

Net Income vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ajanta Pharma Limited Net Income account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Ajanta Pharma's Net Income and Begin Period Cash Flow is 0.7. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Ajanta Pharma Limited, assuming nothing else is changed. The correlation between historical values of Ajanta Pharma's Net Income and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Ajanta Pharma Limited are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Net Income i.e., Ajanta Pharma's Net Income and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.7

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Ajanta Pharma Limited financial statement analysis. It represents the amount of money remaining after all of Ajanta Pharma Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Ajanta Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ajanta Pharma Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajanta Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

As of now, Ajanta Pharma's Selling General Administrative is increasing as compared to previous years. The Ajanta Pharma's current Issuance Of Capital Stock is estimated to increase to about 105 K, while Tax Provision is projected to decrease to under 2.1 B.

	2022	2023	2024	2025 (projected)
Interest Expense	58.4M	72.1M	207.3M	217.7M
Depreciation And Amortization	1.3B	1.4B	1.4B	1.5B

Interest Expense Depreciation And Amortization

Ajanta Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Net Receivables	Short Term Debt	Retained Earnings	Intangible Assets	Other Liab	Net Tangible Assets
Total Assets		-0.53	0.69	0.95	1.0	0.98	-0.85	0.72	0.99	0.44	0.91	-0.62	0.78	0.98	0.21	-0.03	0.95	0.99	0.76	0.9	0.89	-0.7	0.98	0.56	0.97	0.92
Short Long Term Debt Total	-0.53		-0.11	-0.35	-0.58	-0.59	0.66	-0.42	-0.57	-0.2	-0.45	0.01	-0.07	-0.47	0.04	0.16	-0.32	-0.48	-0.46	-0.55	-0.46	0.73	-0.46	-0.01	-0.44	-0.66
Other Current Liab	0.69	-0.11		0.65	0.67	0.64	-0.29	0.14	0.68	0.68	0.56	-0.78	0.8	0.69	0.1	-0.03	0.69	0.68	0.47	0.5	0.66	-0.37	0.72	0.89	0.69	0.49
Total Current Liabilities	0.95	-0.35	0.65		0.92	0.88	-0.82	0.75	0.9	0.41	0.95	-0.65	0.84	0.95	0.18	0.05	1.0	0.97	0.78	0.86	0.87	-0.56	0.96	0.58	0.93	0.83
Total Stockholder Equity	1.0	-0.58	0.67	0.92		0.99	-0.85	0.71	0.99	0.44	0.88	-0.6	0.74	0.97	0.21	-0.05	0.91	0.98	0.75	0.9	0.88	-0.74	0.97	0.53	0.96	0.93
Property Plant And Equipment Net	0.98	-0.59	0.64	0.88	0.99		-0.85	0.71	1.0	0.39	0.84	-0.55	0.68	0.94	0.29	-0.14	0.87	0.94	0.72	0.89	0.81	-0.72	0.93	0.49	0.94	0.93
Net Debt	-0.85	0.66	-0.29	-0.82	-0.85	-0.85		-0.92	-0.84	-0.17	-0.86	0.32	-0.49	-0.82	-0.22	-0.03	-0.78	-0.84	-0.71	-0.82	-0.7	0.73	-0.79	-0.2	-0.8	-0.86
Cash	0.72	-0.42	0.14	0.75	0.71	0.71	-0.92		0.69	0.0	0.77	-0.13	0.43	0.7	0.3	0.11	0.72	0.73	0.69	0.79	0.56	-0.55	0.67	0.05	0.7	0.78
Non Current Assets Total	0.99	-0.57	0.68	0.9	0.99	1.0	-0.84	0.69		0.43	0.85	-0.59	0.72	0.96	0.27	-0.12	0.89	0.96	0.72	0.89	0.83	-0.71	0.95	0.54	0.95	0.92
Non Currrent Assets Other	0.44	-0.2	0.68	0.41	0.44	0.39	-0.17	0.0	0.43		0.38	-0.52	0.51	0.43	-0.02	0.21	0.43	0.44	0.31	0.34	0.47	-0.35	0.46	0.59	0.43	0.3
Cash And Short Term Investments	0.91	-0.45	0.56	0.95	0.88	0.84	-0.86	0.77	0.85	0.38		-0.61	0.73	0.88	0.05	0.08	0.94	0.93	0.81	0.8	0.85	-0.68	0.9	0.52	0.86	0.8
Common Stock Shares Outstanding	-0.62	0.01	-0.78	-0.65	-0.6	-0.55	0.32	-0.13	-0.59	-0.52	-0.61		-0.76	-0.63	0.01	-0.02	-0.68	-0.64	-0.26	-0.27	-0.64	0.31	-0.68	-0.81	-0.63	-0.29
Non Current Liabilities Total	0.78	-0.07	0.8	0.84	0.74	0.68	-0.49	0.43	0.72	0.51	0.73	-0.76		0.84	0.13	0.08	0.88	0.82	0.46	0.63	0.77	-0.3	0.87	0.83	0.86	0.62
Inventory	0.98	-0.47	0.69	0.95	0.97	0.94	-0.82	0.7	0.96	0.43	0.88	-0.63	0.84		0.15	0.01	0.95	0.99	0.7	0.88	0.91	-0.65	0.99	0.59	0.99	0.91
Other Current Assets	0.21	0.04	0.1	0.18	0.21	0.29	-0.22	0.3	0.27	-0.02	0.05	0.01	0.13	0.15		-0.01	0.17	0.16	0.02	0.34	-0.21	0.12	0.14	0.04	0.25	0.25
Other Stockholder Equity	-0.03	0.16	-0.03	0.05	-0.05	-0.14	-0.03	0.11	-0.12	0.21	0.08	-0.02	0.08	0.01	-0.01		0.06	0.04	-0.02	0.03	0.05	0.0	-0.02	0.01	-0.02	-0.06
Total Liab	0.95	-0.32	0.69	1.0	0.91	0.87	-0.78	0.72	0.89	0.43	0.94	-0.68	0.88	0.95	0.17	0.06		0.97	0.75	0.84	0.87	-0.53	0.96	0.63	0.94	0.82
Total Current Assets	0.99	-0.48	0.68	0.97	0.98	0.94	-0.84	0.73	0.96	0.44	0.93	-0.64	0.82	0.99	0.16	0.04	0.97		0.78	0.89	0.92	-0.68	0.99	0.57	0.97	0.9
Common Stock	0.76	-0.46	0.47	0.78	0.75	0.72	-0.71	0.69	0.72	0.31	0.81	-0.26	0.46	0.7	0.02	-0.02	0.75	0.78		0.82	0.75	-0.62	0.72	0.26	0.65	0.77
Accounts Payable	0.9	-0.55	0.5	0.86	0.9	0.89	-0.82	0.79	0.89	0.34	0.8	-0.27	0.63	0.88	0.34	0.03	0.84	0.89	0.82		0.75	-0.64	0.86	0.32	0.87	0.96
Net Receivables	0.89	-0.46	0.66	0.87	0.88	0.81	-0.7	0.56	0.83	0.47	0.85	-0.64	0.77	0.91	-0.21	0.05	0.87	0.92	0.75	0.75		-0.72	0.92	0.56	0.86	0.79
Short Term Debt	-0.7	0.73	-0.37	-0.56	-0.74	-0.72	0.73	-0.55	-0.71	-0.35	-0.68	0.31	-0.3	-0.65	0.12	0.0	-0.53	-0.68	-0.62	-0.64	-0.72		-0.64	-0.19	-0.6	-0.71
Retained Earnings	0.98	-0.46	0.72	0.96	0.97	0.93	-0.79	0.67	0.95	0.46	0.9	-0.68	0.87	0.99	0.14	-0.02	0.96	0.99	0.72	0.86	0.92	-0.64		0.65	0.98	0.89
Intangible Assets	0.56	-0.01	0.89	0.58	0.53	0.49	-0.2	0.05	0.54	0.59	0.52	-0.81	0.83	0.59	0.04	0.01	0.63	0.57	0.26	0.32	0.56	-0.19	0.65		0.61	0.35
Other Liab	0.97	-0.44	0.69	0.93	0.96	0.94	-0.8	0.7	0.95	0.43	0.86	-0.63	0.86	0.99	0.25	-0.02	0.94	0.97	0.65	0.87	0.86	-0.6	0.98	0.61		0.9
Net Tangible Assets	0.92	-0.66	0.49	0.83	0.93	0.93	-0.86	0.78	0.92	0.3	0.8	-0.29	0.62	0.91	0.25	-0.06	0.82	0.9	0.77	0.96	0.79	-0.71	0.89	0.35	0.9

Click cells to compare fundamentals

Ajanta Pharma Account Relationship Matchups

Ajanta Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	37.8B	40.6B	46.8B	46.4B	50.1B	52.7B
Short Long Term Debt Total	313.6M	250.3M	356.3M	352.8M	474.2M	741.0M
Other Current Liab	1.9B	564.7M	(99.2M)	3.4B	5.3B	5.5B
Total Current Liabilities	6.5B	6.5B	11.4B	9.0B	10.0B	10.5B
Total Stockholder Equity	30.0B	32.6B	33.9B	35.7B	37.9B	39.8B
Property Plant And Equipment Net	16.3B	16.5B	17.0B	17.2B	18.9B	19.9B
Net Debt	(1.5B)	(1.8B)	(2.9B)	(942.1M)	(1.3B)	(1.2B)
Cash	1.8B	2.1B	3.3B	1.3B	1.8B	958.4M
Non Current Assets Total	17.5B	17.9B	18.5B	19.1B	21.7B	22.8B
Non Currrent Assets Other	566.8M	497.1M	133.4M	1.5B	2.0B	2.1B
Cash And Short Term Investments	3.8B	3.3B	8.4B	4.6B	6.1B	6.5B
Common Stock Shares Outstanding	130.6M	129.7M	128.1M	126.0M	125.2M	104.7M
Liabilities And Stockholders Equity	37.8B	40.6B	46.8B	46.4B	50.1B	52.7B
Non Current Liabilities Total	1.3B	1.4B	1.5B	1.8B	2.3B	2.4B
Inventory	7.7B	7.9B	8.2B	8.3B	9.0B	9.5B
Other Current Assets	1.4B	1.3B	1.2B	2.0B	1.4B	1.4B
Other Stockholder Equity	8.2B	5.3B	2.2B	2.6M	122.9M	116.8M
Total Liab	7.8B	7.9B	12.9B	10.7B	12.2B	12.9B
Total Current Assets	20.3B	22.6B	28.3B	27.3B	28.4B	29.9B
Accumulated Other Comprehensive Income	8.2B	5.3B	2.2B	2.3B	37.7B	39.5B
Common Stock	173.9M	171.7M	252.7M	251.8M	250.7M	178.0M
Accounts Payable	3.7B	3.3B	4.2B	4.6B	4.5B	2.5B
Net Receivables	7.4B	10.2B	10.6B	12.5B	11.8B	12.4B
Short Term Debt	115.9M	64.6M	94.3M	117.6M	152.9M	145.3M
Retained Earnings	21.6B	27.2B	31.4B	33.1B	36.7B	38.6B
Intangible Assets	107.9M	90.2M	77.5M	146.6M	465.2M	488.5M
Other Liab	726.7M	1.0B	1.1B	1.3B	1.4B	1.5B
Net Tangible Assets	22.4B	25.9B	29.8B	32.6B	37.4B	21.1B
Other Assets	1.1B	1.1B	1.1B	1.4B	2.0B	2.1B
Long Term Debt	6.6M	7.4M	16M	16.4M	12.5M	0.0
Short Term Investments	2.0B	1.2B	5.1B	3.3B	4.4B	4.6B
Short Long Term Debt	900K	2.7M	1.8M	14.9M	25.9M	24.6M
Property Plant Equipment	16.3B	16.5B	17.0B	17.2B	18.9B	13.9B
Current Deferred Revenue	2.3B	2.5B	6.8B	393.2M	452.2M	429.6M
Long Term Debt Total	197.7M	185.7M	262M	235.2M	347.2M	364.6M
Non Current Liabilities Other	33.4M	30M	26.7M	23.4M	20M	26.7M
Net Invested Capital	30.0B	32.7B	33.9B	35.7B	37.9B	33.0B
Net Working Capital	13.8B	16.2B	16.9B	18.4B	18.5B	15.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

SLDP	Solid Power
RIO	Rio Tinto ADR
SQM	Sociedad Quimica y

Other Information on Investing in Ajanta Stock

Balance Sheet is a snapshot of the financial position of Ajanta Pharma Limited at a specified time, usually calculated after every quarter, six months, or one year. Ajanta Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ajanta Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ajanta currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Ajanta Net Income vs Begin Period Cash Flow Analysis

Net Income vs Begin Period Cash Flow

Net Income vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Net Income

Begin Period Cash Flow

Ajanta Pharma fundamental ratios Correlations

Ajanta Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ajanta Pharma fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Ajanta Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity

Cash	- 0.92	Net Debt
Net Tangible Assets	- 0.86	Net Debt
Cash And Short Term Investments	- 0.86	Net Debt
Net Debt	- 0.85	Property Plant And Equipment Net
Net Debt	- 0.85	Total Stockholder Equity
Net Debt	- 0.85	Total Assets